<DOC>
	<DOCNO>NCT00355238</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-582664 shrink slow growth advance liver cancer . The safety treatment also study .</brief_summary>
	<brief_title>A Phase II Open Label Study BMS-582664 Locally Advanced Metastatic Hepatocellular Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Diagnosis hepatocellular carcinoma ( HCC ) â‰¥ 2cm base : Biopsy OR Radiological evidence HCC contrastenhanced CT scan contrastenhanced AND Blood test positive Hepatitis B C AND Alpha fetoprotein &gt; 400 mg/L Not appropriate curative surgery Screening Blood Pressure &lt; 150/100 mmHg , Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % Heart Attack within 12 month , uncontrolled chest pain within 6 month Ascites resistant diuretic medication therapy Portalsystemic encephalopathy Portal hypertension bleed esophageal gastric varix within past 2 month Deficiency sodium blood sodium &lt; 125 mEq/L Subjects serious nonhealing wound , ulcer bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>